Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
about
Seed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related PathwaysIs there a cloud in the silver lining for imatinib?Chronic myeloid leukemia: mechanisms of resistance and treatment.Homoharringtonine: a new treatment option for myeloid leukemia.Homoharringtonine for the treatment of chronic myelogenous leukemia.Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalPharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumorsOmacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.Omacetaxine mepesuccinate in chronic myeloid leukemia.A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Omacetaxine mepesuccinate for the treatment of leukemia.Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
P2860
Q24594585-81D2ED49-60FC-47F7-9542-4E91699B7241Q35097392-3752AE7A-70E6-43D4-9B2A-4F15D4270487Q35595795-3D90020F-FEE1-479B-97DE-8E08D8B39A95Q35994823-C0CCDA1F-A7EC-49BE-8EA6-9CBCCE2DAA01Q37123425-6A4CDD97-B4D8-44E2-889A-170C09E84925Q37179439-2AE01F01-F95E-44B5-80B8-63AF2876A097Q37222797-02B7DCE1-8226-4954-AB96-FD5055A5D9A7Q38123196-2DF7A1F3-0504-48A5-AFFE-184C7BCFFEB8Q38187115-764564AE-A34B-42DF-AF23-DBADD7EEA6F0Q38258641-1A513F6A-FC92-407A-86D6-5F8121FA36CFQ38846325-2AC22164-9251-478B-A380-DDDAA421A351Q39035187-013C8458-9EA9-4D11-B571-D4AC314C4906Q40110805-49C83681-9CC5-4E78-BB8A-DE548F2C013DQ45350588-12CA4DB1-1603-4311-BCD9-CB62647E5CE5Q49887894-B49BCD34-7F5F-425F-A5A4-B73240E81C8DQ52892987-7D1C811D-4D00-4DBC-BD39-E0D8900A08A3Q58449026-5D61782D-D98E-46EE-A579-1982F628DDA6
P2860
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@en
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@nl
type
label
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@en
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@nl
prefLabel
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@en
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Simultaneous homoharringtonine ...... chronic myelogenous leukemia.
@en
P2093
Anthony Murgo
Charles Koller
Deborah Thomas
Francis J Giles
Jianqin Shan
Moshe Talpaz
Steve Kornblau
Susie Mallard
P2860
P304
P356
10.1002/CNCR.10436
P407
P50
P577
2002-04-01T00:00:00Z